$12.21
$2.4 B
FOLD Mkt cap, 20-Sep-2018Amicus Therapeutics EBIT (Q2, 2018)-103.1 M
Amicus Therapeutics Cash, 30-Jun-201873.3 M
Amicus Therapeutics Income Statement
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Revenue | 122.2 m | 1.2 m | 5 m | 36.9 m | |
Revenue growth, % | (99%) | (100%) | |||
Cost of goods sold | 833 k | 6.2 m | |||
Gross profit | 4.1 m | 30.7 m | |||
Gross profit Margin, % | 83% | 83% | |||
R&D expense | 104.8 m | 149.3 m | |||
General and administrative expense | 71.2 m | 88.7 m | |||
Operating expense total | 175.9 m | 472.7 m | |||
Depreciation and amortization | 3.6 m | ||||
EBIT | (405.6 m) | (68.7 m) | (130.4 m) | (181.9 m) | (442 m) |
EBIT margin, % | (332%) | (5613%) | (3669%) | (1197%) | |
Interest expense | 46 k | 1.5 m | 1.6 m | 5.4 m | 17.2 m |
Interest income | 174 k | 223 k | 929 k | 1.6 m | 4.1 m |
Pre tax profit | (449.1 m) | ||||
Income tax expense | 3.5 m | 1.1 m | 1.1 m | 3.7 m | 165.1 m |
Net Income | (378.5 m) | (68.9 m) | (132.1 m) | (200 m) |
- Source: SEC Filings
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 39 k | 456 k | 475 k | 293 k | 456 k | 475 k | 293 k | |||||
Cost of goods sold | 344 k | 775 k | 1.8 m | |||||||||
R&D expense | 10.1 m | 10 m | 10 m | 12 m | 16.1 m | 17.2 m | 21 m | 23.4 m | 18.3 m | 32.5 m | 30.9 m | |
General and administrative expense | 4.6 m | 5.2 m | 4.8 m | 5.3 m | 6.4 m | 8.3 m | 15.4 m | 15.7 m | 19.3 m | 17.5 m | 19.1 m | |
Operating expense total | 15.2 m | 16.1 m | 14.7 m | 17.1 m | 24.1 m | 26.9 m | 38 m | 43 m | 48.5 m | 46.7 m | 55.4 m | 284.3 m |
EBIT | (15.1 m) | (15.6 m) | (14.3 m) | (16.8 m) | (24.1 m) | (26.9 m) | (38 m) | (43 m) | (48.5 m) | (44.9 m) | (52 m) | (275.2 m) |
EBIT margin, % | (38808%) | (3426%) | (3003%) | (5739%) | (5276%) | (5672%) | (12985%) | |||||
Interest expense | 7 k | 355 k | 374 k | 377 k | 372 k | 338 k | 17 k | 945 k | 1.1 m | 1.5 m | 4.3 m | 4.4 m |
Interest income | 36 k | 42 k | 36 k | 55 k | 171 k | 158 k | 316 k | 307 k | 331 k | 460 k | 759 k | 1.2 m |
Income tax expense | 453 k | 253 k | (56 k) | |||||||||
Net Income | (14.6 m) | (15.9 m) | (14.6 m) | (17.1 m) | (24.3 m) | (27.1 m) | (37.8 m) | (43.7 m) | (51.1 m) | (46.7 m) | (55 m) | (214.8 m) |
- Source: SEC Filings
Amicus Therapeutics Balance Sheet
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Cash | 43.6 m | 24.1 m | 69.5 m | 187 m | 49.1 m |
Accounts Receivable | 1.3 m | 9.5 m | |||
Inventories | 5.5 m | 2.9 m | 2.6 m | 3.4 m | 4.6 m |
Current Assets | 88.3 m | 154.6 m | 216.6 m | 340.1 m | 392 m |
Goodwill | 11.6 m | 11.6 m | 197.8 m | 197.8 m | 197.8 m |
Total Assets | 127.6 m | 210 m | 908.4 m | 1 b | 627 m |
Accounts Payable | 10.2 m | 16.3 m | 32.2 m | 185.5 m | |
Short-term debt | |||||
Current Liabilities | 10.5 m | 20.2 m | 73.6 m | 111 m | 70 m |
Long-term debt | |||||
Additional Paid-in Capital | 423.6 m | 568.7 m | 917.5 m | 1.1 b | 1.4 b |
Retained Earnings | (447.4 m) | (579.6 m) | (779.6 m) | (1.1 b) | |
Total Equity | 45.8 m | 122.2 m | 347.8 m | 360.2 m | 352.9 m |
Financial Leverage | 2.8 x | 1.7 x | 2.6 x | 2.9 x | 1.8 x |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 30 m | 27.5 m | 41.9 m | 19.7 m | 28.8 m | 249 m | 19.4 m | 23.5 m | 63.7 m | 33.1 m | 44.8 m | 37.4 m | 64.1 m | 114.3 m | 73.3 m |
Accounts Receivable | 864 k | 1.9 m | 3.8 m | 6 m | 10.8 m | 15.1 m | |||||||||
Inventories | 194 k | 3.3 m | 3.7 m | 3.9 m | 7.3 m | 8.1 m | 7.8 m | ||||||||
Current Assets | 64.3 m | 73.5 m | 79.4 m | 87.2 m | 151.3 m | 365 m | 240.1 m | 168.5 m | 217.7 m | 221.7 m | 296.2 m | 241 m | 431 m | 592 m | 576.2 m |
Goodwill | 11.6 m | 11.6 m | 11.6 m | 11.6 m | 11.6 m | 207.6 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m | |
Total Assets | 69.1 m | 112.4 m | 118 m | 125.5 m | 192.6 m | 403.9 m | 986.7 m | 862.9 m | 914 m | 918.2 m | 993.4 m | 939 m | 680.8 m | 870 m | 825.9 m |
Accounts Payable | 8.2 m | 9.2 m | 9.9 m | 11.3 m | 15.8 m | 16.9 m | 30.6 m | 22.5 m | 23.8 m | 29 m | |||||
Current Liabilities | 8.6 m | 9.4 m | 11.2 m | 13.8 m | 21 m | 16.9 m | 35.9 m | 64.4 m | 80.5 m | 85.6 m | 109.6 m | 100.7 m | 68.2 m | 140.7 m | 53 m |
Total Liabilities | 348.4 m | 264 m | |||||||||||||
Additional Paid-in Capital | 392.2 m | 424.8 m | 444.6 m | 468.7 m | 574.8 m | 826.6 m | 914.3 m | 921.2 m | 990 m | 1 b | 1.1 b | 1.1 b | 1.4 b | 1.6 b | 1.7 b |
Retained Earnings | (409.1 m) | (426.2 m) | (471.7 m) | (498.9 m) | (536.7 m) | (623.3 m) | (674.3 m) | (721 m) | (834.6 m) | (882.7 m) | (994.4 m) | (1.1 b) | (1.2 b) | ||
Total Equity | 26.5 m | 31.1 m | 36.3 m | 43.3 m | 104 m | 328.9 m | 378.8 m | 311.6 m | 334.2 m | 336.6 m | 310.8 m | 266.9 m | 409.7 m | 521.6 m | 561.9 m |
Financial Leverage | 2.6 x | 3.6 x | 3.2 x | 2.9 x | 1.9 x | 1.2 x | 2.6 x | 2.8 x | 2.7 x | 2.7 x | 3.2 x | 3.5 x | 1.7 x | 1.7 x | 1.5 x |
Amicus Therapeutics Cash Flow
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Net Income | (59.6 m) | (68.9 m) | (132.1 m) | (200 m) | (284 m) |
Depreciation and Amortization | 1.7 m | 1.5 m | 1.8 m | 3.2 m | 3.6 m |
Accounts Receivable | (1.4 m) | (7.7 m) | |||
Inventories | (3.2 m) | 2.3 m | 308 k | (3.7 m) | (897 k) |
Accounts Payable | 6.2 m | 15.5 m | 7.1 m | ||
Cash From Operating Activities | (45.8 m) | (51.7 m) | (100.1 m) | (150.5 m) | (215.5 m) |
Purchases of PP&E | (695 k) | (238 k) | (4.8 m) | (6 m) | (4.5 m) |
Cash From Investing Activities | (145.3 m) | (4.5 m) | (171.2 m) | ||
Cash From Financing Activities | 139.2 m | 290.9 m | 272.7 m | 247.4 m | |
Interest Paid | 30 k | 1.2 m | 605 k | 3 m | 7.4 m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (47.4 m) | (15.9 m) | (30.6 m) | (47.7 m) | (24.3 m) | (51.4 m) | (89.2 m) | (43.7 m) | (94.7 m) | (141.4 m) | (55 m) | (103.1 m) | (214.8 m) | (49.9 m) | (111.8 m) |
Depreciation and Amortization | 1.3 m | 412 k | 808 k | 1.2 m | 508 k | 861 k | 1.3 m | 673 k | 1.4 m | 2.3 m | 823 k | 1.6 m | 969 k | 1.9 m | |
Accounts Receivable | (863 k) | (512 k) | (2.2 m) | 6 m | (1 m) | (6 m) | |||||||||
Inventories | (207 k) | (3.5 m) | (243 k) | (351 k) | 7.3 m | (3.3 m) | (3.4 m) | ||||||||
Accounts Payable | (679 k) | (987 k) | (155 k) | 1.2 m | (551 k) | 459 k | 14.1 m | (9.8 m) | (8.2 m) | (2.9 m) | (1.3 m) | ||||
Cash From Operating Activities | (37.7 m) | (10.2 m) | (22 m) | (37.2 m) | (21 m) | (43.6 m) | (64.6 m) | (44.9 m) | (77.7 m) | (118.5 m) | (49.8 m) | (91.8 m) | (141.7 m) | (49.5 m) | (106.5 m) |
Purchases of PP&E | (645 k) | (40 k) | (132 k) | (192 k) | (753 k) | (1.4 m) | (2.2 m) | (2.9 m) | (4.6 m) | (5.5 m) | (732 k) | (2.3 m) | |||
Cash From Investing Activities | (5.8 m) | 2.1 m | (27.3 m) | 31.3 m | (230.7 m) | (39.9 m) | (92.4 m) | (48.9 m) | (222.8 m) | (182.6 m) | (171.9 m) | ||||
Cash From Financing Activities | (85 k) | 18.2 m | 40.5 m | 4.1 m | 237.2 m | 290.7 m | 82.8 m | 122.4 m | (95 k) | 240.6 m | 296.6 m | 303.6 m | |||
Interest Paid | 24 k | 208 k | 537 k | 864 k | 209 k | 605 k | 605 k | 209 k | 276 k | 284 k | 12 k | 3.7 m | 3.7 m | 12 k | 3.8 m |
Free Cash Flow | (50.3 m) | (108.4 m) |
Amicus Therapeutics Ratios
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.5 x |
Report incorrect company information
